Pharma News, 2019

Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion

Data show J&J’s Invokana may slow or prevent CKD in diabetes patients

AZ finds lack of lung cancer info available for patients

Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria

ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression b

FDA Approves Dovato (dolutegravir/lamivudine) for HIV-1 Infection

FDA Approves Evenity (romosozumab-aqqg) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk of Fracture

FDA issues final rule on safety and effectiveness of consumer hand sanitizers

Intercept Reports Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH

French court finds Bayer's Monsanto liable for farmer's sickness

Large study ties PTSD, acute stress to cardiovascular disease

Four million new child asthma cases linked to traffic pollution